Condition: Triple Negative Breast Cancer · Sponsor: Centre Henri Becquerel
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.
This description comes directly from the study's public registry record.
Florian Clatot, MD, PhD · +33276673004 · florian.clatot@chb.unicancer.fr
Doriane Richard, PhD · +33232082985 · doriane.richard@chb.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Henri Becquerel | Rouen, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06879704